Abstract
ObjectiveTo evaluate the clinical performance of the novel PivNG primers and probes set (PivNG test) used in the cobas omni Utility Channel for supplemental testing ofNeisseria gonorrhoeae(NG).MethodsOropharyngeal, urogenital and rectal samples were self-collected during routine testing at Barts Health sexual health clinics, London, UK. Samples were tested by the cobas CT/NG test and PivNG cobas omni Utility Channel test on cobas 6800/8800 Systems. Supplemental testing was carried out with the Xpert CT/NG test. PivNG overall percent agreements, positive percent agreements (PPAs)/negative percent agreements (NPAs) and positive/negative predictive values were calculated for each sample type. Microscopy and/or culture data were included for a randomised subset of concordant/discordant results, and a composite reference standard (cobas CT/NG, Xpert CT/NG and culture results) adjusted for partial verification bias was used to determine PivNG PPA and NPA.ResultsOf 447 evaluable samples with valid results from all three assays (cobas CT/NG, PivNG and Xpert CT/NG), 288 (64.4%) were NG-positive by both PivNG and cobas CT/NG; 117 (26.2%) were NG-negative in both tests; and 42 (9.4%) had discordant results (with NG-negative supplementary Xpert) CT/NG results in 40/42 instances). Of 19 PivNG/Xpert CT/NG-discordant samples, 11 were confirmed NG-positive by microscopy and/or culture results. PivNG PPA and NPA were 100% and 91% for oropharyngeal swabs, 100% and 100% for vaginal swabs, 100% and 100% for male urine samples, and 100% and 97% for rectal swabs, respectively, compared with the partially adjusted composite reference standard.ConclusionsPivNG is a reliable supplementary test with high sensitivity for confirming NG infection when used in conjunction with the cobas CT/NG test and samples collected in cobas PCR Media. Moreover, the PivNG test offers a convenient, high-throughput solution for supplemental NG testing of various sample types, with the potential to reduce the number of indeterminate reports.
Subject
Infectious Diseases,Dermatology
Reference10 articles.
1. WHO . Sexually transmitted infections (STIs). 2021. Available: https://www.who.int/news-room/fact-sheets/detail/sexually-transmitted-infections-(stis)
2. Meyer T , Buder S . The laboratory diagnosis of Neisseria gonorrhoeae: current testing and future demands. Pathogens 2020;9:91. doi:10.3390/pathogens9020091
3. 2018 UK national guideline for the management of infection with Neisseria gonorrhoeae
4. England Public Health . Guidance for the detection of gonorrhoea in england. 2021. Available: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/972388/Guidance_for_the_detection_of_gonorrhoea_in_England_2021.pdf
5. High-throughput testing of urogenital and extragenital specimens for detection of Chlamydia trachomatis and Neisseria gonorrhoeae with cobas® CT/NG;Marlowe;Eur J Microbiol Immunol (Bp),2017
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献